glp-1 receptor agonist with dpp-4 inhibitor combination not recommended Table 2 from DPP- 4 Inhibitors in the Management of Type 2 Diabetes Mellitus Differences between GLP-1 receptor agonists
Description
The 2016 LEADER (NCT01179048) trial was the first to demonstrate a modest cardiovascular benefit in patients with T2D and stable cardiovascular disease receiving liraglutide, when compared to placebo
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis
Algorithm for patients presenting for elective surgery while taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
an anti-diabetic medication causing small bowel obstruction
doi: 10.5483/BMBRep.2020.53.1.279 72 LiQLiuYSunM
Anecdotal evidence suggests that GLP-1 RAs may be beneficial in IBD treatment
